Effect of simvastatin on endothelial function in cardiac syndrome X patients

Patients with cardiac syndrome X with mild hypercholesterolemia were randomized to placebo (n = 20) or simvastatin 20 mg/day (n = 20). In the simvastatin group, there was a significant (26%; p <0.0001) decrease in total cholesterol, a 38% (p <0.0001) decrease in low-density lipoprotein cholesterol levels, and 7% a (p <0.0001) increase in high-density lipoprotein cholesterol levels, without significant changes in triglyceride levels. Brachial artery flow-mediated dilation increased significantly (52% relative increase, p <0.0001), and the time to >1-mm ST-segment depression during stress testing was longer by the end of the study (p <0.0001).